Table 2.
Some antineoplastic drugs, substrates of polymorphic enzymes analyzed in this research (http://www.pharmacologyweekly.com/content/pages/cytochrome-cyp-p450-enzyme-medication-herbs-substrates; Quiñones et al., 2008).
| Drugs | Enzyme | Cancer |
|---|---|---|
| Cisplatin | GSTM, GSTT | Breast |
| Cyclophosphamide | CYP2B6, CYP2C19, CYP3A4 | Leukemia, lymphoma |
| Dacarbazine | CYP1A1, CYP1A2, CYP2E1 | Melanoma, sarcoma, lymphoma |
| Docetaxel | CYP2C8, CYP3A, CYP1B1 | Breast, lung, stomach |
| Doxorubicin | CYP3A4 | Sarcoma |
| Ellipticine | CYP3A4, CYP1A | Leukemia, myeloma, lymphosarcoma |
| Etoposide | CYP3A4, CYP2E1, CYP1A2 | Testicle, lung, breast, leukemia, lymphoma |
| Ifosfamide | CYP2B6, CYP3A4 | Sarcoma, testicle |
| Imatinib | CYP3A4, CYP3A5 | Leukemia |
| Irinotecan | CYP3A4/5 | Colon and rectum |
| UGT1A1 | ||
| Methotrexate | MTHFR | Leukemia |
| Mitoxantrone | CYP3A4, CYP1B1 | Leukemia, lymphoma |
| Paclitaxel | CYP2C8, CYP3A4 | Breast, lung, ovary |
| Phortress (2-(4-aminophenyl-benzotiazol) | CYP1A1, CYP1B1 | Ovary, breast |
| Procarbazine | CYP1A1, CYP2B6 | Lymphoma, brain, lung, melanoma, testicle |
| Tamoxifen | CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1B1, UGT2B7 | Breast |
| Tegafur | CYP2A6, CYP2C8, CYP1A2 | Colon, rectum, stomach |
| Teniposide | CYP2C19, CYP3A4/5 | Leukemia, lung, brain, bladder, myeloma |
| Thiotepa | CYP2B6, CYP3A4 | Bladder |
| Topotecan | CYP3A4/5 | Ovary, lung |
| Vinblastine | CYP3A4/5 | Lymphoma, osteosarcoma |
| Vincristine | CYP3A4/5 | Lymphoma |
| Vindesine | CYP3A4/5 | Lung |
| Vinrelbine | CYP3A4/5 | Lung |